Verona Pharma Appoints Stifel as Nominated Adviser
LONDON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to announce the appointment of Stifel Nicolaus Europe Limited as its Nominated Adviser and Sole Broker with immediate effect.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer | info@veronapharma.com |
| Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7710 7600 |
| Stewart Wallace / Jonathan Senior / Ben Maddison | SNELVeronaPharma@stifel.com |
| ICR, Inc. (US Media and Investor Enquiries) | |
| Darcie Robinson | Tel: +1 203 682 8379 |
| Darcie.Robinson@icrinc.com | |
| Stephanie Carrington | Tel: +1 646 277 1282 |
| Stephanie.Carrington@icrinc.com | |
| FTI Consulting (UK Media and Investor Enquiries) | Tel: +44 (0)20 3727 1000 |
|
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins |
veronapharma@fticonsulting.com |
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Verona Pharma plc via GlobeNewswire